Prevention Effect of Different Doses of Simvastatin on Esophagus Cancer of Barrett's Esophagus Patients

CAO Hui-qiong; GU Xin; MA Song-yan

doi:10.14033/j.cnki.cfmr.2015.23.007

Abstract：Objective:To explore the prevention effect of different doses of Simvastatin on esophagus cancer of Barrett's esophagus patients. Method:228 patients with Barrett's esophagus from January our hospital from January, 2004 to January, 2009 were divided into group A and group B and group C by digital random method, 76 cases in each group. All patients were treated with proton pump inhibitors(PPI), and on the basis of PPI therapy, group A and group B combined with Simvastatin 20 mg/d and 40 mg/d respectively. All the patients received 5 years follow up. The treatment time was 9 months. Barrett's esophagus cure effect, Barrett esophagus occurrence and complications occurrence of three groups were statistical analyzed.Result:Patients rate with significant, good, normal and bad curative effect and total treatment efficient in 3 groups had no statistical significance (P>0.05). Esophagus cancer incidence of group C was 13.16%, which werehigher than the6.58% of group A and 5.26% of group B, and the difference was statistically significant (P<0.05). The esophagus cancer incidence of group A and group B had no statistical significant difference (P>0.05). the incidence of chronic cough, base layer cell hyperplasia and other complications and total complications incidence of group A and group C had no statistical significant difference (P>0.05), while the incidence of abnormal liver function and muscle related disease and total complication incidence of group B were higher than that of group A and group C, and the difference was statistically significant (P<0.05).Conclusion:20 mg Simvastatin used in the treatment of Barrett's esophagus can effectively prevent the happening of esophagus cancer without increasing the risk of complications, thus 20 mg Simvastatin can be used as one of auxiliary medication to prevent esophagus cancer.